- Lexaria received its 25th patent – and the first patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs
- The company is seeking IND approval from the FDA and has commenced its human HYPER-H21-4 study for hypertension with DehydraTECH-CBD, with results expected in Q3 2022
- Lexaria is also commencing its human oral nicotine study, NIC-H22-1 to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the US such as ON! and Zyn
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has announced some positive news that further promotes the company’s goal of creating innovative drug delivery alternatives with its proprietary patented DehydraTECH(TM) technology. Lexaria is making the delivery of drugs quicker, more efficient, and even tasting better.
The company was granted its 25th patent – the first received for the use of its DehydraTECH technology for the enhanced delivery of antiviral drugs. The official word was received from the…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]
CBDWire is part of the InvestorBrandNetwork.